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IFN-gammaThe liver lymphocyte population is enriched with natural killer (NK) cells, which play a key role in host defense
against viral infection and tumor transformation. Recent evidence from animal models suggests that NK cells also
play an important role in inhibiting liver ﬁbrosis by selectively killing early or senescence activated hepatic stellate
cells (HSCs) and by producing the anti-ﬁbrotic cytokine IFN-γ. Furthermore, clinical studies have revealed that
human NK cells can kill primary human HSCs and that the ability of NK cells from HCV patients to kill HSCs is en-
hanced and correlates inversely with the stages of liver ﬁbrosis. IFN-α treatment enhances, while other factors
(e.g., alcohol, TGF-β) attenuate, the cytotoxicity of NK cells against HSCs, thereby differentially regulating liver
ﬁbrogenesis. In addition, the mouse liver lymphocyte population is also enriched for natural killer T (NKT) cells,
whereas human liver lymphocytes have a much lower percentage of NKT cells. Many studies suggest that NKT
cells promote liver ﬁbrogenesis by producing pro-ﬁbrotic cytokines such as IL-4, IL-13, hedgehog ligands, and
osteopontin; however, NKT cells may also attenuate liver ﬁbrosis under certain conditions by killing HSCs and by
producing IFN-γ. Finally, the potential for NK andNKT cells to be used as therapeutic targets for anti-ﬁbrotic therapy
is discussed. This article is part of a Special Issue entitled: Fibrosis: Translation of basic research to human disease.
Published by Elsevier B.V.1. Introduction
Liver ﬁbrosis and its end-stage consequence, cirrhosis, represent
the ﬁnal common pathway of virtually all chronic liver diseases and
affect hundreds of millions of people worldwide. Despite impressive
advancements in the ﬁeld, no treatment options currently exist to
cure ﬁbrosis, with the exception of liver transplantation. The complex
mechanisms driving the progression of chronic liver injury to ﬁbrosis
are not fully understood because of the multifaceted and often para-
doxical intercellular relationships. Accumulating evidence suggests
that hepatic stellate cell (HSC) activation during liver injury is a key
step in the development of liver ﬁbrosis [1–5]. In a healthy liver,
HSCs are quiescent and play a central role in the storage of retinol
(vitamin A compound). After injury, HSCs become activated and
transdifferentiate into matrix-producing cells termed myoﬁbroblasts.
The activation of HSCs is controlled by many types of cytokines,
growth factors, immune cells, and other factors [1–5]. Among theDC, Dendritic cell; DDC,
atic stellate cell; iNKT, invari-
ionine choline-deﬁcient diet;
alcoholic steatohepatitis; NK
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.V.immune cells involved, macrophages have been shown not only to
contribute to the pathogenesis of liver ﬁbrosis but also to promote
liver ﬁbrosis resolution [6]. Dendritic cells (DCs) were reported to
exacerbate liver ﬁbrosis via the production of TNF-α by an early
paper [7], but a recent study using more speciﬁc DC markers suggests
that DCs ameliorate liver ﬁbrosis by promoting ﬁbrosis regression via
the secretion of matrix metalloproteinase-9 [8]. Additionally, the
functions of natural killer (NK) and NKT cells in liver ﬁbrogenesis
have recently received great attention because these cells are
enriched among liver lymphocytes and are also markedly altered in
various liver diseases [9]. In this review, we highlight recent advances
in the understanding of the functions of NK and NKT cells that are
important for the pathogenesis of liver ﬁbrogenesis and will brieﬂy
discuss NK and NKT cells as potential therapeutic targets for anti-
ﬁbrotic therapy.
2. NK and NKT cell biology
NK cells are lymphocytes of the innate immune system that recog-
nize and kill infected and tumorigenic cells. These cells represent a
third lineage of lymphoid cells that is distinct from T and B cells.
Unlike B and T cells, NK cells do not express an antigen receptor. In-
stead, they rely upon an array of cell surface receptors to detect
changes in the expression of host cell surface molecules that typically
appear on a variety of ‘stressed cells’, including microbe- or virus-
infected cells, transformed cells, and injured cells [10]. The decision
to kill a cell is made based on the net balance of signals delivered by
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cells. The inhibitory receptors include killer Ig-like receptors (KIRs)
and Ly-49A and CD94/NKG2 receptors that recognize MHC class I
molecules (inhibitory ligands) expressed on nearly all normal cells,
which subsequently inactivate NK cell function. Thus, NK cells do
not kill normal host cells. The stimulatory receptors present on NK
cells include NKp46, NKp30 and NKp44, which are collectively
referred to as natural cytotoxicity receptors, NKG2D, and DNAX
accessory molecule-1 (CD226) [10–12]. Among these, NKG2D is the
most well-deﬁned receptor, which binds its ligands (e.g., MICA/B
and ULBP in humans, RAE-1 and MULT1 in mice) that are expressed
on target cells and subsequently promotes NK cell activation. After
activation, NK cells can directly kill target cells via the exocytosis of
perforin- and granzyme-containing cytoplasmic granules. NK cells
can also kill target cells in a perforin-independent manner by utilizing
FAS ligand, TNF-α, and TNF-related apoptosis-inducing ligands
(TRAIL). Additionally, production of many cytokines (particularly
IFN-γ, TNF-α, IL-10, IL-22) and chemokines (including MIP-1α and
-β and RANTES) is another important mechanism by which NK cells
regulate target cells and immune responses [13,14].
NKT cells are a heterogeneous group of T lymphocytes that recog-
nize lipid antigens presented by the nonclassical MHC class I-like mole-
cule CD1 [15]. Human tissues express ﬁve distinct isoforms of CD1,
including CD1a, -b, -c, -d, and -e, whereas mice only express CD1d.
The CD1d-dependent NKT cells can be grouped into two types of cells:
type I and type II NKT cells. Type I NKT cells, which are also called clas-
sical or invariant NKT (iNKT) cells because they express an invariant T
cell receptor α (TCR-α) chain, comprise 95% of liver NKT cells. Type II
NKT cells express diverse TCRs and make up less than 5% of liver NKT
cells. Upon activation by lipid antigens such as α-galactosylceramide
(α-GalCer), iNKT cells are able to produce large quantities of IFN-γ,
IL-4, IL-13, TNF-α, IL-17, and many other cytokines. Activated iNKT
cells also produce cytotoxic mediators such as perforin, Fas ligand, and
TRAIL to kill target cells. Although activation of iNKT cells by the exoge-
nous lipid antigen α-GalCer has been extensively investigated, the en-
dogenous ligands that activate NKT cells remain largely unknown.
3. Hepatic NK and NKT cells
NK cells in the liver, which were originally called “Pit” cells in rats,
are located in the hepatic sinusoids in close vicinity to liver non-
parenchymal cells and represent a unique organ-associated NK cell
population [16]. Under normal physiological conditions, hepatic NK
cells have a rapid turnover, with an estimated residence time of 1 to
2 weeks in the liver. Because their proliferative activity is very low,
the hepatic NK cell population is continuously replenished from an
extra-hepatic source of stem cells, which is most likely located in
the bone marrow [16]. The frequency of NK cells among liver lympho-
cytes is much higher in rats and humans than that in mice; in mice,
10% of hepatic lymphocytes are NK cells, while 30–50% of liver
lymphocytes from rat and human livers are NK cells [9]. Various
pathological conditions (such as viral infection, acute and chronic
inﬂammation) as well as treatments with biological response
modiﬁers that activate the immune system (such as polyinosinic–
polycytidylic acid [poly I:C] or IFNs) signiﬁcantly increase the number
of NK cells in the liver (see review [9] and reference therein). At
present, the mechanisms underlying the enrichment of NK cells in
the liver are not fully understood, although it is believed that adhe-
sion to sinusoidal endothelial cells is an important step in the recruit-
ment of NK cells from the vascular compartment into the liver [17].
Such adhesion is regulated by cell adhesionmolecules, whichmediate
cell-to-cell and cell-to-matrix interactions. In humans, several cell ad-
hesion molecules, such as CD11a/CD18, CD2, CD54, CD56, and CD58,
have been detected on the surface of NK cells [18], and blocking
these molecules with neutralizing antibodies markedly decreases
the number of NK cells in the liver [17].After migrating into the liver, peripheral NK cells develop into
liver-speciﬁc NK cells with unique features, such as higher levels of
cytotoxicity against different tumor target cells, compared to NK
cells from other organs [19,20]. Such liver-speciﬁc NK cell develop-
ment is believed to be controlled by the liver sinusoidal microenvi-
ronment. For example, human NK cells extracted from normal
donor liver perfusates from a living donor liver transplantation were
able to kill human hepatocellular carcinoma cell line HepG2 cells,
an effect which was further enhanced by IL-2 treatment; however,
NK cells from recipient livers with cirrhosis showed impaired
anti-tumor activity even in the presence of IL-2 stimulation [19]. At
present, how liver microenvironment affects liver-speciﬁc NK cell
development remains unclear.
In addition to NK cells, NKT cells are also enriched among liver
lymphocytes, as approximately 30–35% of mouse liver lymphocytes
are NKT cells, and 5–10% of rat and human liver lymphocytes are
NKT cells, which are signiﬁcantly larger frequencies than that ob-
served for peripheral blood lymphocytes (b5% NKT cells) [9]. NKT
cells not only directly kill target cells but also produce a wide variety
of cytokines, thereby playing diverse roles in controlling liver injury,
ﬁbrosis, regeneration, and hepatocarcinogenesis [9].
4. Anti-ﬁbrotic effect of NK cells
NK cell killing of activated HSCs was ﬁrst demonstrated by two
different groups using mouse models in 2006 [21,22], and this obser-
vation was later conﬁrmed by many additional studies both in
animal models [23–32] and patients [28,31,33–36] (Table 1). Collec-
tively, these ﬁndings suggest that NK cells selectively kill early
activated (transitional) or senescence-activated HSCs but do not
kill quiescent or fully activated (myoﬁbroblasts) HSCs (Fig. 1). In
addition, NK cells also produce IFN-γ, which then induces HSC
apoptosis and cell cycle arrest and subsequently inhibits liver ﬁbro-
sis (Fig. 1).
4.1. NK cells selectively kill early activated but not quiescent or fully
activated HSCs: In vivo and in vitro evidence
In a healthy liver, HSCs are quiescent and store retinol, but in re-
sponse to liver injury, they are activated and converted into highly pro-
liferative, contractile myoﬁbroblast-like cells [3]. Activation of HSCs in
an injured liver gives rise to an array of cells at different stages of activa-
tion and trans-differentiation that display transitional phenotypes, gene
expression, and functions, which can be identiﬁed by several markers.
Among these, Desmin, an intermediate ﬁlament typical of contractile
cells, has been widely used as the “gold standard” for identifying all
stages of HSCs in rodent livers, although its expression in humans is
unreliable [3]. As illustrated in Fig. 2A, immunostaining with Desmin
showsnumerous processes in thequiescentHSCs,while the early activat-
ed HSCs in the ﬁbrotic mouse livers induced by 3,5-diethoxycarbonyl-
1,4-dihydrocollidine (DDC) are identiﬁed as small round cells with a
scant cytoplasm that lack the processes. The myoﬁbroblast-like cells are
revealed as elongated shape and localized in the portal ﬁbrotic areas.
Immunohistochemistry analyses have shown in vivo that NK cells
kill early activated, but not quiescent or fully activated, HSCs. First, the
number of early activated desmin positive HSCs with an oval shape
was signiﬁcantly decreased in DDC-fed mice after administration of
the NK cell activator poly I:C (Radaeva and Gao, unpublished data). Sec-
ond, immunohistochemistry analyses show that early activated HSCs
and NK cells have similar distributions throughout zones II and III of
the liver parenchyma but do not reside in the periportal ﬁbrotic area
(Fig. 2B–C). Third, the direct contact between NK cells and early activat-
ed HSCs is often observed in the injured liver (Fig. 2D).
In vitro cell co-culture and cytotoxicity assays clearly demonstrate
that NK cells kill early activated, but not quiescent or fully activated,
HSCs (Fig. 1) [24]. Quiescent HSCs are spontaneously activated
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vided into early and chronic stages of activation based on cell mor-
phology and gene expression. HSCs cultured for 4–7 days become
characteristically early activated HSCs and gradually lose their stores
of retinol, whereas cells cultured for long periods of time (21 days) be-
come fully activated HSCswithmyoﬁbroblast-like functionality. In vitro
cytotoxicity assays show that NK cells only kill days 5–7 cultured HSCs
but not freshly isolated quiescent HSCs or day 21-cultured HSCs,
suggesting that NK cells selectively kill early activated HSCs [24]. Fur-
thermore,we have provided evidence suggesting that during activation,
early activated HSCs produce retinoic acid, which upregulates the NK
cell activating ligand retinoic acid inducible gene 1 (RAE1) expression
on HSCs. RAE1 binds NKG2D on NK cells and subsequently activates
NK cells to kill the early activated HSCs through TRAIL- and NKG2D-
dependent mechanisms [21,24]. In contrast, chronically activated HSCs
or myoﬁbroblasts lose their cytoplasmic stores of retinol and do not pro-
duce RA and RAE1, thereby gaining resistance to NK cell killing. Similar to
mouse models, NK cells from HCV-infected patients effectively induce
the apoptosis of activated HSCs through TRAIL-, Fas L-, and NKG2D-
dependentmechanisms [34]. In addition, TRAIL receptor expression is el-
evated in HSCs after activation [37], which likely also contributes to the
increased sensitivity of these activated HSCs to NK cell killing.Table 1
The major ﬁndings related to the anti-ﬁbrotic effects of NK cells.
The references Animal model or human studies Major ﬁ
Radaeva et al. [21]
2006
DDC-feeding or CCl4 treatment in mice; mouse
NK-HSC co-culture
In vivo d
ﬁbrosis
In vitro
mechan
Melhem et al. [22]
2006
CCl4 treatment in mice; human NK-LX2 co-culture In vivo l
In vitro
Jeong et al. [23]
2006
CCl4 treatment in mice; mouse NK-HSC co-culture Activatio
ﬁbrosis.
Radaeva et al. [24]
2007
Mouse NK-HSC co-culture Co-cultu
of the N
Krizhanovsky et al. [25]
2008
CCl4 treatment in mice; co-culture of NK-IMR-90
ﬁbroblasts or primary human myoﬁbroblasts
The num
of NK ce
In vitro
Jeong et al. [26]
2008
Chronic ethanol feeding plus CCl4 treatment in mice Feeding
Hintermann et al. [27]
2010
CCl4 treatment in mice CXCL10-
ﬁbrosis.
Yoshida et al. [33]
2011
Peripheral lymphocytes from HCV patients Blood N
ﬁbrosis
Muhanna e al [28]
2011
Human NK-LX2 co-culture;
CCl4 treatment in mice
Knockdo
antiﬁbro
Jeong et al. [29]
2011
CCl4 treatment in mice;
mouse NK-HSC co-culture
Fully act
NK cells
Hou et al. [30]
2012
Schistosoma japonicum egg-induced liver ﬁbrosis in
mice; mouse NK-HSC co-culture
In vivo d
NK cells
In vitro
Sagiv A et al. [32]
2012
Human NK-HSC co-culture;
CCl4 treatment in mice
Co-cultu
mechan
CCl4 adm
Gur et al. [31]
2012
CCl4 treatment in mice; mouse NK-HSC co-culture;
human NK-HSC co-culture
High lev
KO mice
In vitro
Co-cultu
Glassner et al. [34]
2012
Human NK-HSC co-culture;
liver biopsies from HCV patients
NK cells
human
An inve
apoptos
Kramer et al. [35]
2012
Analyses of intra- and extra-hepatic NK cells from
HCV patients; ﬁbrosis was determined on biopsies
Accumu
had high
frequen
Eisenhardt et al. [36]
2012
Analyses of peripheral NK cells from HCV patients;
co-culture primary human HSCs-HCV patient NK cells
In health
CXCR3−
of CXCR
IFN-γ seApart from NKG2D, the NK cell activating receptor NKp46 and its
mouse ortholog NCR1 are also involved in controlling liver ﬁbrosis
through the killing of primary human and mouse HSCs, respectively
[31]. NKp46, a unifying marker for NK cells across mammalian species,
recognizes viral hemagglutinins and unknown cellular ligands [38]. Re-
cently, Gur et al. [31] demonstrated that, in the absence of NKp46,
non-activated NK cell killing of HSCs was completely abolished, al-
though activated NK cells remained able to kill HSCs, suggesting that
NKp46 plays a critical role inmediating the non-activatedNK cell killing
of HSCs and that other receptors (such as NKG2D) contribute to the ac-
tivated NK cell killing of HSCs.
Furthermore, the increased sensitivity of activated HSCs to NK cell
killing may also be due to changes in NK cell inhibitory ligand expres-
sion [22]. Following CCl4-induced ﬁbrosis, activated HSCs lose expres-
sion of the MHC-1 antigen, which is an NK cell inhibitory ligand that
suppresses NK cell function by binding the inhibitory killer-cell
immunoglobulin-like receptors (iKIRs) on NK cells. Consequently,
these activated HSCs become sensitive to NK cell killing [22]. The im-
portant role of iKIRs in attenuating the NK cell-mediated anti-ﬁbrotic
effect is supported by the ﬁnding that silencing iKIR via the transfec-
tion of iKIR siRNA enhances NK cell killing of HSCs and restrains liver
ﬁbrosis [28].ndings
epletion of NK cells exacerbated, while activation of NK cells ameliorated, liver
in mouse models.
co-culture with NK cells killed activated HSCs through NKG2D- and TRAIL-dependent
isms.
iver ﬁbrosis was exacerbated in mice with NK cell deﬁciency.
co-culture with NK cells killed activated HSCs in a granzyme B-dependent manner.
n of STAT1 by IFN-γ augmented NK cell killing of HSCs, thereby attenuating liver
re with NK cells selectively killed early activated HSCs that expressed elevated levels
K cell-activating ligand retinoic acid inducible early gene 1 (RAE1).
ber of senescence-activated HSCs in CCl4-treated mice was increased after depletion
lls but was decreased following administration of the NK cell activator poly I:C.
co-culture with NK cells killed senescence-activated HSCs.
mice with an ethanol diet abrogated the anti-ﬁbrotic effect of NK cells and IFN-γ.
deﬁcient mice had more NK cells in the liver and were resistant to CCl4-induced liver
K cell percentages were decreased in HCV patients and inversely correlated with liver
progression, which was monitored by counting platelets.
wn of the NK cell inhibitory receptor iKIR stimulated NK cells and promoted their
genic activity in mice and human HSC co-cultures.
ivated HSCs were resistant to NK cell killing via the production of TGF-β that inhibited
.
epletion of NK cells enhanced S. japonicum-induced liver ﬁbrosis, while activation of
inhibited it.
co-culture with NK cells killed activated HSCs.
re with NK cells killed senescence-activated HSCs through a perforin-dependent
ism. Perforin KO mice had increased liver ﬁbrosis compared to WT mice after chronic
inistration.
els of NCR1 (murine orthologue of the NKp46) were detected on murine HSCs. NCR1
were more susceptible to CCl4-induced liver ﬁbrosis.
co-culture with murine NK cells killed mouse HSCs in an NCR1-dependent manner.
re with human NK cells killed human HSCs in an NKp46-dependent manner.
from HCV patients were highly efﬁcient at inducing apoptosis of activated primary
HSCs in vitro in TRAIL-, FasL- and NKG2D-dependent manners.
rse correlation between liver ﬁbrosis stages and the ability of NK cells to induce HSC
is in HCV patients was observed.
lation of NKp46high NK cells was found in the HCV-infected livers. NKp46high NK cells
er levels of cytolytic activity and IFN-γ secretion than NKp46dim NK cells, and the
cy of intrahepatic NKp46high NK cells was inversely correlated with ﬁbrosis stages.
y controls, CXCR3+CD56bright NK cells had stronger activity against HSCs than
CD56dim NK cells. Chronic HCV infection was associated with an increased frequency
3+CD56bright NK cells, but these cells showed impaired degranulation and impaired
cretion in response to HSCs.
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activators
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Fig. 1. Mechanisms underlying the anti-ﬁbrotic effect of NK cells. NK cells can be activated by several TLR ligands and cytokines. Early and senescence-activated HSCs express
elevated levels of NK cell-activating ligands that bind several NK activating receptors on NK cells, including NKG2D (mice and human), NCR1 (mice), and NKp46 (human), and sub-
sequently induce NK cell activation. Activated NK cells release cytotoxic mediators that selectively kill early or senescence-activated HSCs but not quiescent or fully activated HSCs.
Activated NK cells also produce IFN-γ, which not only directly induces HSC death but also further enhances NK cell cytotoxicity against HSCs. Quiescent and fully activated HSCs do
not express elevated NK cell-activating ligands and are resistant to NK cell killing.
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Activated HSCs can become senescent and demonstrate stable cell
cycle arrest, reduced levels of extracellular matrix components, and
the upregulation of extracellular matrix-degrading enzymes, which is
an important step in limiting the ﬁbrogenic response to tissue damage
[25,39]. Senescent HSCs accumulate in the ﬁbrotic scar area after chron-
ic liver injury. Depletion of NK cells increased the number of senescent
HSCs, while activation of NK cells by injection of poly I:C reduced those
senescent HSCs in the ﬁbrotic livers from chronic CCl4-treated mice
[25]. This is because senescence-activated HSCs express elevated levels
of NK cell-activating ligands and become sensitive toNK cell killing [25].
SuchNK cell killing ismediated via the granule exocytosis pathway [32],
which is different from the TRAIL pathway involved in theNK cell killing
of early activated HSCs [21].
4.3. NK cells restrict liver ﬁbrosis by producing cytokines (e.g., IFN-γ)
Production of a large amount of IFN-γ is a hallmark of activated NK
cells and mediates many of the functions of NK cells, such as anti-viral
and anti-tumor defense. Recent evidence suggests that production of
IFN-γ also contributes signiﬁcantly to the anti-ﬁbrotic effect of NK
cells by directly inducing HSC apoptosis and cell cycle arrest [23,40]
and enhancing NK cell killing of activated HSCs [21] (Fig. 1).
In addition to IFN-γ, NK cells also producemany other cytokines and
chemokines; however, the mechanisms by which these mediators
affect the anti-ﬁbrotic effects of NK cells remain largely unknown. For
example, blood-derived NK cells and mucosa-associated lymphoid
tissue-residing NK cells (also called NK-22 cells) produce IL-22 [41], a
cytokine that has been shown to protect against liver injury and inhibit
liver ﬁbrosis [42,43]. Thus, it would be interesting to examine whether
activated NK cells from diseased livers produce IL-22 and whether the
production of IL-22 contributes to the anti-ﬁbrotic effect of NK cells.
5. The diverse and complex roles of NKT cells in liver ﬁbrogenesis
In contrast to the consistent results of NK cell-mediated anti-ﬁbrotic
effects, the functions of NKT cells in the pathogenesis of liver ﬁbrosis
seem more complex and likely play diverse roles due to the following
reasons. First, there are several types of NKT cells, including type I and
type II NKT cells, which play different roles and sometimes opposing
functions in the liver [9,44,45]. Second, the detection of NKT cells after
activation is more difﬁcult than that of NK cells because of the rapid
downregulation of NKT cell markers and/or apoptosis after activation
[46,47]. Third, the mechanisms by which NKT cells are activated by en-
dogenous ligands and cytokines in vivo remain largely unknown [48].Fourth, after activation, NKT cells become tolerant and nonresponsive
to subsequent stimulation [49–51]. Finally, activated NKT cells can pro-
duce large amounts of both anti-ﬁbrotic (e.g., IFN-γ) and pro-ﬁbrotic
(e.g., IL-4, IL-13, hedgehog ligands, and osteopontin) cytokines, as well
as many other cytokines, chemokines, and mediators that can differen-
tially regulate liver ﬁbrogenesis (Fig. 3).
Table 2 lists themajor recent studies that have evaluated the roles of
NKT cells in liver ﬁbrogenesis. The ﬁrst study discussing NKT cells and
liver ﬁbrosis was conducted in HCV patients in 2004 [52], and the au-
thors reported that the number of intrahepatic iNKT cells, the hepatic
expression of CD1d, and the production of pro-ﬁbrotic IL-4 and IL-13
cytokines by iNKT cells were signiﬁcantly increased in HCV patients
with cirrhosis. Based on these ﬁndings, the authors concluded that
iNKT cells responded to the progressive liver damage caused by chronic
HCV infection and subsequently promoted liver ﬁbrosis via the produc-
tion of pro-ﬁbrotic cytokines. Investigation into the roles of NKT cells
in liver ﬁbrogenesis using animal models has begun only recently
(Table 2). Most of these studies relied on two strains of NKT-deﬁcient
mice: Jα18 KO mice (with a deﬁciency in type I iNKT cells) and CD1d
KO mice (with a deﬁciency in both type I iNKT and type II NKT cells).
5.1. CCl4-induced liver ﬁbrosis model
The functions of iNKT cells in liver ﬁbrogenesis have been extensive-
ly investigated in a mouse model of CCl4-induced liver ﬁbrosis in Jα18
KOmice [53]. This study revealed that Jα18 KOmiceweremore suscep-
tible to CCl4-induced acute liver injury and inﬂammation, suggesting
that iNKT cells protect against CCl4-induced acute liver injury. Such pro-
tection is likely mediated via the iNKT suppression of HSC activation
and cytokine production. In contrast, treatment with α-GalCer induced
strong iNKT cell activation and enhanced CCl4-induced acute liver inju-
ry and ﬁbrosis. In amodel of chronic liver injury induced by chronic CCl4
administration, Jα18 KO and wild-type mice had comparable degree of
liver injury, with only a slightly higher grade of liver ﬁbrosis in Jα18 KO
mice than wild-type mice at 2 weeks, but not 4 weeks, after CCl4 injec-
tion. Chronic α-GalCer treatment induced iNKT tolerance and had little
effect on liver injury and ﬁbrosis in themodel of chronic CCl4 challenge.
In summary, iNKT cells seem to play diverse roles in controlling liver
ﬁbrogenesis. Different degrees of iNKT activation, including acute and
chronic iNKT activation, may differentially regulate the development
and progression of liver ﬁbrogenesis.
5.2. Thioacetamide (TAA)-induced liver ﬁbrosis
Chronic TAA treatment is another model of chemical-induced liver
ﬁbrosis. Ishikawa et al. [54] reported that CD1dKO mice were resistant
AB
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(Normal liver parenchyma) 
D
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Fig. 2. In vivo evidence for the contact between NK cells and early activated HSCs. (A): Identiﬁcation of early activated/transitional HSCs and NK cells in the ﬁbrotic livers from
DDC-fed mice. Under the light microscope, early activated desmin-positive cells (arrows in the middle panel) appear as small cells with scant cytoplasm and lack numerous pro-
cesses typical for quiescent HSCs (arrows in the left panel). Bars, 50 μm. (B): Mice were fed a DDC diet for 2 weeks. Liver sections were stained with desmin and Ly49G antibodies to
identify HSCs and NK cells, respectively. Positive staining was developed using either 3,3′-diaminobenzidine containing nickel chloride (black staining for HSCs) or
3-amino-9-ethylcarbazole (red staining for NK cells). Note that positive cells occupied a similar area of the liver parenchyma, including zones 2 and 3. (C): Higher magniﬁcation
of HSCs and NK cells located in the perisinusoidal space of Disse and in the hepatic sinusoid, respectively. (D): Double immunostaining of NK cells and HSCs demonstrating that
Ly49G-positive NK cells (red) are located in close proximity to desmin-positive (black) early activated HSCs. Bars, 50 μm.
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proposed that CD1d-restricted NKT cells, including type I (iNKT) and
type II NKT cells, not only produce IL-4 and IL-13, which directly
induce HSC activation and liver ﬁbrosis, but also produce IFN-γ, which
stimulates macrophage activation and liver inﬂammation, thereby pro-
moting liver injury and liver ﬁbrosis.
5.3. Nonalcoholic fatty liver disease (NAFLD)-associated liver ﬁbrosis
The role of NKT cells in high fat diet (HFD)-induced obesity, insulin
resistance, and fatty liver disease has been extensively investigated in
C56BL/6 mice, but the results have been controversial [55–59]. In addi-
tion, in murine models of obesity-associated fatty liver, hepatic NKT
cells are decreased [60–62], whereas human NAFLD is associated with
increased NKT cell accumulation in the liver [63–65]. The reasons un-
derlying such opposite changes in liver NKT cells are not clear but
may be related to differences in the pathogenesis and severity of liver
disease inmouse fatty liver and humanNAFLD. It is believed that the ac-
cumulation of NKT cells in human NAFLD is due to hepatic hedgehog
pathway activation, and such NKT cell accumulation exacerbates liver
ﬁbrosis [63].
C57BL/6 mice are the best strain to study HFD-induced obesity and
insulin resistance, although these animals do not develop HFD-induced ﬁbrosis. In contrast, BALB/c mice are resistant to HFD-induced
obesity and insulin resistance but are sensitive to HFD-induced ﬁbrosis.
Feeding BALB/c mice with a HFD induced mild liver inﬂammation and
ﬁbrosis, which was exacerbated in Jα18 KO mice on a BALB/c back-
ground [66]. This result suggests that iNKT cells play a hepatoprotective
and anti-ﬁbrotic role in HFD-induced NAFLD in mice on a BALB/c
background.
Feeding a methionine choline-deﬁcient (MCD) diet induces fatty
liver, inﬂammation, and ﬁbrosis in rodents, which mimics the severe
form of nonalcoholic steatohepatitis (NASH) that occurs in some
humans. Using this model, Dr. Diehl's group demonstrated that NKT
cells play an important role in promoting liver ﬁbrogenesis via the
production of hedgehog ligands and osteopontin that promote HSC
activation and ﬁbrogenesis [63,67].
5.4. HBV-transgenic mice
HBV-transgenic mice, C57BL/6J-TgN (AlbHBV)44Bri, which contain
HBV genome S, pre-S, and X domains, develop spontaneous liver ﬁbro-
sis with enhanced expression of collagen I, matrix metalloproteinase,
and tissue inhibitor of metalloproteinase [68]. HBV-transgenic mice
were also shown to be more susceptible to CCl4-induced liver injury
and ﬁbrosis, with an accumulation and overactivation of NKT cells in
++ 
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Fig. 3. Mechanisms underlying the complex roles of NKT cells in liver ﬁbrogenesis. NKT cells can be activated by lipid antigens (such as α-GalCer) presented by CD1d on antigen
presenting cells (APCs). In addition, several cytokines can also activate NKT cells. Activated NKT cells rapidly produce a wide variety of anti-ﬁbrotic and pro-ﬁbrotic mediators that
attenuate and enhance liver ﬁbrosis, respectively. The net effect of NKT cells is reﬂected by the balance between the anti- and pro-ﬁbrotic effects of NKT cells. Thus, NKT cells may
play different roles in the control of liver ﬁbrogenesis in different stages and different types of liver diseases. OPN: osteopontin; Hh: hedgehog ligands.
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liver injury and ﬁbrosis in theHBV-transgenicmice [68], which suggests
that NKT cells promote liver ﬁbrosis in this model via the production of
IL-4 and IL-13 [68].
6. NK cells and liver ﬁbrosis in human liver diseases
Current studies from animal models suggest that NK cells inhibit
liver ﬁbrosis. Interestingly, several recent studies have implied that
NK cells may play an even greater role in controlling liver ﬁbrosis
in patients with chronic liver diseases compared to that observed
usingmousemodels. First, human liver lymphocytes are approximately
30–50% NK cells, which is a much higher frequency than that of the
mouse liver lymphocyte population (approximately 10% NK cells).
Second, liver NK cells are not signiﬁcantly altered in most models of
liver ﬁbrosis in rodents, whereas the functions of NK cells are signiﬁ-
cantly altered under many conditions in patients with liver disease,
such as viral hepatitis, IFN-α therapy, chronic alcohol consumption,
and cirrhosis. Herein, we discuss the potential implications of NK cells
in the pathogenesis of liver ﬁbrosis in patients.
6.1. Viral hepatitis
The activation and function of NK cells in the pathogenesis of HCV
infection have been extensively investigated in the past ﬁve years.
Most of these studies have suggested that during HCV infection,
virally-infected hepatocytes produce IFN-α/β and other cytokinesTable 2
The major ﬁndings related to NKT cells and liver ﬁbrosis.
The references Models Major ﬁndings
de Lalla et al. [52]
2004
Analyses of circulating and liver
iNKT in HCV patients
iNKT cells were increased in chron
proﬁbrotic IL-4 and IL-13 cytokine
elicited IL-4 and IL-13.
Park et al. [53]
2009
CCl4 treatment in mice Jα18 KO mice had a higher grade
injection. Administration of the iN
ﬁbrosis but had no effects in the c
Miyagi et al. [66]
2010
Mouse model (HFD feeding) Jα18 KO mice were more susceptib
Syn et al. [63]
2010
Mouse model (MCD feeding);
Human NASH cirrhotic livers
NASH cirrhotic livers had higher n
Patched-deﬁcient mice with an ac
while CD1d KO mice had decrease
Jin et al. [68]
2011
Mouse model (HBV TG mice) NKT cells were over-activated in c
adaptive transfer of NKT cells enh
Ishikawa et al. [54]
2011
Mouse model (chronic TAA
injection)
CD1d KO mice had decreased live
administration.
Syn et al. [67]
2012
Mouse model (MCD diet feeding) Jα18 KO and CD1d KO mice had s
ﬁbrosis compared to WT mice in a(e.g., IL-12, IL-15, IL-18), which induce peripheral blood NK cell acti-
vation and enhance NK cell cytotoxicity [35,69–74]. In addition,
IFN-α therapy has been shown to rapidly induce the activation of pe-
ripheral NK cells in HCV patients [74–77]. However, the regulation of
intrahepatic NK cells during chronic HCV infection remains obscure
due to the availability of liver biopsy and the lack of appropriate
control liver samples. A number of studies [35,70,76] have shown
that intrahepatic NK cells possess greater cytotoxic activity than
peripheral blood NK cells in HCV patients, which is consistent with
previous ﬁndings showing that healthy livers contain NK cells with
higher basal levels of cytotoxicity compared to peripheral NK cells
[19,20]. Interestingly, a recent study reported that in comparison to
intrahepatic NK cells from patients undergoing surgery for uncompli-
cated gallstone, intrahepatic NK cells from patients with chronic HCV
infection demonstrated lower levels of cytotoxicity [78]. This result
suggests that intrahepatic NK cell activity during HCV infection is
suppressed compared to that in healthy livers, despite the fact that
these cells exhibited higher activity than peripheral NK cells. Thus,
further studies are needed to conﬁrm these ﬁndings.
The anti-viral function of NK cells has been well documented for
many years. Thus, activated NK cells likely play an important role in
controlling/preventing HCV infection by killing HCV-infected hepato-
cytes, inhibiting HCV replication, or by priming the adaptive immune
response [73,79,80]. Recently, Dr. Nattermann's group published
three interesting papers, which suggest that human NK cells also
play a critical role in restricting liver ﬁbrosis in HCV patients by killing
HSCs [34–36].Suggested
functions
ically HBV- or HCV-infected livers with preferential production of
s. In vitro CD1d-dependent activation of iNKT cells from healthy donors
Pro-ﬁbrotic
of ﬁbrosis than WT mice at 2 weeks, but not 4 weeks, after CCl4
KT activator α-GalCer accelerated CCl4-induced acute liver injury and
hronic model. Incubation with NKT cells killed HSCs in vitro.
Pro-ﬁbrotic
Anti-ﬁbrotic
le to HFD-induced inﬂammation and ﬁbrosis (on a BALB/c background). Anti-ﬁbrotic
umbers of NKT cells compared to healthy livers.
cumulation of liver NKT cells had increased liver ﬁbrosis,
d liver ﬁbrosis in a model of MCD feeding.
Pro-ﬁbrotic
hronic CCl4-treated HBV TG mice. Depletion of NKT cells reduced, while
anced, CCl4-induced liver injury and ﬁbrosis.
Pro-ﬁbrotic
r inﬂammation, injury, and ﬁbrosis compared to WT mice after TAA Pro-ﬁbrotic
igniﬁcantly reduced hedgehog and osteopontin expression and less
model of MCD diet feeding.
Pro-ﬁbrotic
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from untreated HCV RNA(+) patients, IFN-α-treated patients, and
healthy controls were puriﬁed and subsequently incubated with acti-
vated primary human HSCs. This incubation induced NK cell degran-
ulation/activation, with only negligible secretion of IFN-γ and TNF-α,
and subsequently promoted HSC apoptosis through TRAIL-, FasL-, and
NKG2D-dependent mechanisms. Peripheral blood CD56+CD3− NK
cells from IFN-α-treated patients demonstrated the highest level of
cytotoxicity against human HSCs, followed by those from untreated
HCV RNA(+) patients and healthy controls. In addition, the ability
of NK cells to induce HSC apoptosis correlated inversely with the
stages of liver ﬁbrosis [34].
In the second paper published by this group [35], peripheral blood
and intrahepatic CD56+CD3− NK cells from patients with chronic
HCV, NASH, or autoimmune hepatitis, were puriﬁed and analyzed for
the expression of NKp46, amajor humanNK cell activating receptor. Pe-
ripheral blood and intrahepatic NKp46high NK cells demonstrated
higher cytolytic activity against HSCs and stronger IFN-γ secretion in
vitro than NKp46Dim NK cells. Liver lymphocytes were also associated
with a higher frequency of NKp46high cells but lower frequency of
NKp46dim cells compared to those present in the peripheral blood.
Moreover, the frequency of intra-hepatic NKp46high NK cells was in-
versely correlated with HCV RNA levels and ﬁbrosis stages.
In the latest paper from Dr. Nattermann's group [36], the expression
of CXCR3 was analyzed on peripheral blood NK cells from HCV patients
and healthy controls. Based on CXCR3 expression, NK cellswere divided
into CXCR3+ and CXCR3− NK cell groups. In healthy controls, CXCR3+
CD56bright NK cells displayed stronger cytotoxicity activity against HSCs
than CXCR3+CD56dim NK cells. However, in HCV patients, both
CXCR3+CD56bright and CXCR3+CD56dim NK cells had similar activities,
whichwere lower than that of CXCR3+CD56bright NK cells from healthy
controls. This seems not in agreement with the conclusion from their
ﬁrst study that CD56+CD3− NK cells from HCV patients were more ef-
fective in the induction of HSC apoptosis than NK cells from healthy
controls [34].
Taken together, these clinical studies suggest that activated
human HSCs can stimulate human NK cell activation, the latter of
which conversely kills activated human HSCs, and this process plays
an important role in inhibiting liver ﬁbrosis. IFN-α treatment in-
creases the ability of human NK cells from HCV patients to kill activat-
ed HSCs. However, the differences in cytotoxicity against HSCs
between NK cells from HCV-infected patients and normal healthy
controls were somewhat inconsistent between studies [34–36], al-
though this may be explained by the different subsets of NK cells
that were examined, the different treatments of NK cells, and the pa-
tients with different stages of ﬁbrosis who were investigated in these
studies.
6.2. Alcoholic liver disease
Chronic alcohol consumption is a leading cause of chronic liver
disease, which can lead to liver ﬁbrosis and cirrhosis [81]. It has also
been well documented that alcohol consumption accelerates the pro-
gression of liver ﬁbrosis in patients with chronic hepatitis C. Multiple
mechanisms have been implicated in the pathogenesis of alcoholic
liver ﬁbrosis and the alcohol acceleration of liver ﬁbrosis in HCV pa-
tients [81–83]. Because chronic alcohol consumption suppresses NK
cell function, it is plausible that such inhibition contributes to the pro-
gression of alcoholic liver ﬁbrosis. Indeed, feeding mice an ethanol
diet markedly inhibited NK cell cytotoxicity against HSCs and exacer-
bated liver ﬁbrosis [26], and this result was due to ethanol inhibition
of TRAIL, NKG2D, and IFN-γ expression by NK cells [26]. In addition, it
would be interesting to determine whether the ability of NK cells to
kill HSCs is also suppressed in patients with alcoholic liver disease
or HCV patients with alcohol consumption and whether IFN-α treat-
ment can restore the cytotoxicity of NK cells against HSCs.6.3. Cirrhosis
Despite NK cell-mediated protection against ﬁbrosis, chronic liver
injury still leads to ﬁbrosis and cirrhosis, which suggests that HSCs
may employ speciﬁc mechanisms to escape from NK cell-mediated
lysis under many conditions. One such mechanism appears to involve
fully activated HSC and myoﬁbroblast production of high levels of
TGF-β, which is one of the most potent inhibitors for NK cells and pre-
vents NK cell killing of HSCs [29].
7. NKT cells and liver ﬁbrosis in human liver diseases
Mouse liver lymphocytes are approximately 30–40% NKT cells,
whereas human liver lymphocyte populations may contain much
lower percentages of NKT cells. The percentage of NKT (CD56+CD3+)
cells among human liver lymphocytes has been shown to be highly
variable, ranging from 3% to 15% [63,84], and CD1d-dependent NKT
cells were found to make up b1% of human liver lymphocytes [84,85].
Although treatment of mice with α-GalCer induces signiﬁcant liver in-
ﬂammation and injury [50], phase I/II clinical trials revealed that injec-
tion of α-GalCer did not produce any signs of liver injury in humans
[85–87]. This result suggests that human liver lymphocytesmay contain
a low percentage of NKT cells and that these cells may play a less signif-
icant role in the pathogenesis of liver ﬁbrosis in patients.
NKT cells from HCV patients without cirrhosis produce both
anti-ﬁbrotic (IFN-γ) and pro-ﬁbrotic (IL-4 and IL-13) cytokines,
whereas NKT cells from cirrhotic HCV patients preferentially produce
IL-4 and IL-13. Thus, it is thought that NKT cells promote liver ﬁbrosis
in HCV patients [52]. The number of NKT cells is signiﬁcantly elevated
in NASH-related cirrhosis, and such elevation is believed to promote
liver ﬁbrogenesis in patients with NASH [63]. Because these cells pro-
duce a wide variety of cytokines and cytotoxic mediators, NKT cells
likely play complex and even opposing roles in controlling liver
ﬁbrogenesis in patients with chronic liver diseases with different
stages and different etiologies. Further clinical studies are needed to
clarify such complex functions of NKT cells.
8. NK/NKT cells as potential therapeutic targets for anti-ﬁbrotic
therapy
Studies in the last 6 years from animal models and patients clearly
indicate that NK cells have strong anti-ﬁbrotic activity, which sug-
gests that the induction of NK cell activity could represent a novel
strategy to treat liver ﬁbrosis [88]. Several cytokines are known to
stimulate NK cell activation, including IFN-α/β, IL-2, IL-12, IL-15,
IL-18, and IFN-γ. Among these, IFN-α/β has the greatest ability to in-
duce NK cell activation, and IFN-α therapy has been shown to poten-
tiate NK cell killing of activated HSCs in HCV patients [34]. Thus,
IFN-α, as an NK activator and a direct inhibitor of HSCs, is a promising
option for anti-ﬁbrotic therapy in patients with viral hepatitis or
other etiologies. Indeed, early studies revealed that IFN-α therapy im-
proved liver ﬁbrosis in HCV patients who responded to anti-viral
therapy, as well as in non-responders who did not clear HCV infection
[89,90]. However, a recent large, multicenter 5-year trial of low-dose
IFN-α showed no beneﬁt of this therapy on liver ﬁbrosis in patients
with chronic HCV infection and advanced ﬁbrosis with or without
cirrhosis [91]. This lack of beneﬁcial effect of low-dose of IFN-α
therapy may be due to the observation that advanced ﬁbrosis is asso-
ciated with high levels of TGF-β, which inhibits a low-dose of
IFN-α-mediated activation of NK cells [29]. Moreover, many current
ongoing anti-ﬁbrotic clinical trials are examining the effects of
IFN-α alone or IFN-α in combination with other drugs [92]. It would
be interesting to include studies during these trials to determine
whether peripheral and intrahepatic NK cells are activated after
IFN-α therapy and if such activation is correlated with an improve-
ment in liver ﬁbrosis in patients. IL-12 and IL-18 are also strong NK
1068 B. Gao, S. Radaeva / Biochimica et Biophysica Acta 1832 (2013) 1061–1069cell activators, but treatment with IL-12 and IL-18 induces signiﬁcant
liver inﬂammation and injury [93] and is therefore not a good strate-
gy to treat liver ﬁbrosis.
In addition to NK cell activators, many factors have been shown to
attenuate NK cell cytotoxicity against HSCs. For example, TGF-β,
alcohol consumption, and NK cell inhibitory receptors were reported
to suppress NK cell killing of HSCs [26,28,29]. Removal of these inhib-
itory factors may present additional promising strategies for the
treatment liver ﬁbrosis. For example, siRNA knockdown of iKIR
enhanced NK cell function and promoted NK cell anti-ﬁbrogenic ac-
tivity in mice and in co-culture with human NK-HSCs, and this tech-
nique has been proposed as a therapeutic option for anti-ﬁbrotic
therapy [28].
The NKT activator α-GalCer was also used in phase I/II clinical tri-
als to treat viral hepatitis but did not show any anti-viral effects
[86,87]. However, liver ﬁbrosis was not investigated in these studies.
Because these cells produce a large variety of cytokines and cytotoxic
mediators that play complex and possibly opposing roles in modulat-
ing liver ﬁbrosis, NKT cells will be difﬁcult to use as a therapeutic
target for anti-ﬁbrotic treatments.References
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